TY  - GEN
AU  - Kato,Shumei
AU  - Jardim,Denis L
AU  - Johnson,Faye M
AU  - Subbiah,Vivek
AU  - Piha-Paul,Sarina
AU  - Tsimberidou,Apostolia M
AU  - Falchook,Gerald S
AU  - Karp,Daniel
AU  - Zinner,Ralph
AU  - Wheler,Jennifer
AU  - Janku,Filip
AU  - Fu,Siqing
AU  - Lim,JoAnn
AU  - Bean,Stacie
AU  - Nguyen,Ly
AU  - Urban,Susan
AU  - Browne,Elsa
AU  - Meric-Bernstam,Funda
AU  - Hong,David S
TI  - Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer
SN  - 1573-0646
PY  - 2019///0225
KW  - Adult
KW  - Aged
KW  - Antineoplastic Agents
KW  - adverse effects
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Crizotinib
KW  - Dasatinib
KW  - Female
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Staging
KW  - Neoplasms
KW  - drug therapy
KW  - Protein Kinase Inhibitors
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
UR  - https://doi.org/10.1007/s10637-017-0513-5
ER  -